Pharma BD Deal Intelligence
GSK's $2B swing at MASH landed early validation: efimosfermin alfa earned Breakthrough Therapy designation and EMA Priority Medicines status by April 2026, with the pivotal ZENITH-1 trial recruiting ~1,200 patients—though primary completion isn't estimated until March 2028.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Once a diffuse organization with at least 15 assets in its pipeline, Boston Pharma made a liver disease program its top priority in recent years under the…
GSK has agreed to acquire efimosfermin alfa from Boston Pharmaceuticals for up to $2 billion, paying $1.2 billion upfront for the Phase 3-ready FGF21 analog.…
Efimosfermin receives US FDA Breakthrough Therapy and EMA PRIME designations for MASH; Phase 3 ZENITH-1/ZENITH-2 ongoing in F2/F3, F4 trials expected to start.
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
GSK acquired efimosfermin alfa from Boston Pharmaceuticals for $1.2B upfront and up to $800M in success-based milestones (total up to $2B), with success-based milestones and tiered royalties also payable to Novartis Pharma AG; the acquisition completed on 7 July 2025. Efimosfermin is a once-monthly subcutaneous FGF21 analog for metabolic dysfunction-associated steatohepatitis (MASH) including compensated cirrhosis, with future development planned in alcohol-related liver disease. Since the deal closed, the Phase 3 program has begun: the pivotal ZENITH-1 study (NCT07221227) in biopsy-confirmed F2/F3 MASH started 24 October 2025 and is recruiting (~1,200 participants; primary completion estimated March 2028), with companion F2/F3 and cirrhotic (F4) studies following. In April 2026 GSK reported that efimosfermin received US FDA Breakthrough Therapy designation and EMA Priority Medicines (PRIME) designation in MASH. GSK continues to guide to a potential first launch in 2029.
14M US cases/yr · $25.0B Global MASH market (2030 projected) · ~20-25% MASH patients progressing to cirrhosis
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is the progressive inflammatory form of steatotic liver disease driven by obesity, type 2 diabetes, and insulin resistance. Left untreated, MASH progresses through fibrosis stages F1-F3 to cirrhosis (F4), decompensation, and hepatocellular carcinoma, and it is projected to become the leading indication for liver transplant in the United States. Madrigal's resmetirom (Rezdiffra, a THR-beta agonist) received the first-ever FDA approval for MASH in non-cirrhotic F2-F3 fibrosis in March 2024, proving that histologic improvement translates to an approvable regulatory path. The unmet need remains largest in F4 compensated cirrhosis where no therapy is yet approved, where decompensation risk is highest, and where FGF21 analog mechanisms have shown the most compelling fibrosis-reversal signals. GSK's rationale for paying up to $2B for Boston Pharmaceuticals' efimosfermin alfa is entry into MASH - including cirrhosis - via a once-monthly FGF21 analog with a Phase 3-ready package, compelling Phase 2 fibrosis regression data, and a monthly dosing differentiator versus weekly competitors.
The MASH competitive landscape is now commercially active and rapidly stratifying by mechanism. THR-beta agonists are led by Madrigal Pharmaceuticals' resmetirom (Rezdiffra), the first and only FDA-approved MASH therapy. FGF21 analogs - the class efimosfermin alfa joins - include Akero Therapeutics' efruxifermin (EFX, weekly SC, Phase 3 SYMMETRY in cirrhotic MASH), 89bio's pegozafermin (weekly SC, Phase 3), and Boehringer Ingelheim's BI 456906 survodutide (dual GLP-1/glucagon with FGF21-like effects). GLP-1 and incretin-based approaches are reshaping the upstream metabolic funnel: semaglutide (Wegovy/Ozempic, Novo Nordisk - ESSENCE MASH trial positive), tirzepatide (Mounjaro/Zepbound, Eli Lilly), retatrutide (Eli Lilly triple agonist), and survodutide (Boehringer Ingelheim/Zealand). FGF19 analogs include NGM Bio's aldafermin (development paused) and Inventiva's lanifibranor (pan-PPAR, Phase 3). Emerging mechanisms include acetyl-CoA carboxylase inhibitors (firsocostat, Pfizer's ervogastat), FASN inhibitors (Sagimet's denifanstat), and THR-alpha-sparing agents. GSK's thesis with efimosfermin is that monthly dosing plus cirrhotic MASH efficacy delivers a best-in-class FGF21 profile.
GSK started the pivotal Phase 3 ZENITH-1 study (NCT07221227) of efimosfermin alfa in biopsy-confirmed F2/F3 MASH (~1,200 participants; primary completion est. March 2028), advancing the acquired 'Phase 3-ready' asset into active Phase 3.
GSK reported that efimosfermin received US FDA Breakthrough Therapy designation and EMA Priority Medicines (PRIME) designation for MASH, supporting an accelerated regulatory path.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Boston Pharmaceuticals Inc. (this deal) | 2025 | $2.0B | — |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2025 deals · GSK plc deals · Gastroenterology deals